Scienture Holdings, Inc. (DE:4E4)
NASDAQ:4E4
4E4 Stock Chart & Stats
€0.30
€2.84(70.70%)
At close: 4:00 PM EST
€0.30
€2.84(70.70%)
Day’s Range― - ―
52-Week Range€0.07 - €1.90
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€12.69M
Enterprise Value-€3.53B
Total Cash (Recent Filing)€3.54B
Total Debt (Recent Filing)€10.00M
Price to Earnings (P/E)―
Beta2.35
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding40,630,814
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.12
Price to Sales (P/S)181.35
P/FCF Ratio>-0.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Recent Balance SheetVery low debt-to-equity in 2025 and TTM materially reduces near-term solvency risk and gives the company financial flexibility to fund commercialization and working capital without immediate debt servicing pressure. This durability supports execution through product launch windows.
Long-term Patent & Exclusive U.S. Commercialization RightsA granted patent with expiry in 2041 plus exclusive U.S. commercialization rights gives a durable intellectual-property and market-access edge. Combined with Summit manufacturing, this positions Scienture to capture sustained revenue if Rezenopy attains market adoption with limited direct product competition.
High TTM Gross Margin And Sharp Revenue UptickHigh TTM gross margin and a marked revenue uplift indicate favorable unit economics for recent product(s). If the company controls operating overhead and scales commercial spend efficiently, those gross margins can translate to durable EBITDA improvement as revenues become repeatable post-launch.
Bears Say
Material Cash Burn And Negative Cash GenerationSustained negative operating and free cash flow means the business is consuming capital rather than self-funding growth. Over months this forces reliance on external financing, compresses runway, limits ability to invest in commercialization, and raises dilution or refinancing risk under strained terms.
Tight Structured Financing With Onerous CovenantsThe structured financing provides near-term liquidity but embeds major operational constraints: broad collateral, tight SEC/listing/capital covenants, triggers that can accelerate balances or raise rates up to 18%. These clauses reduce strategic flexibility and raise downside risk if performance or reporting slips.
Finance Leadership Turnover / Concentrated Management RolesThe CFO resignation and interim appointment of the Co-CEO as finance lead concentrates strategic and financial control. While experienced, this consolidates responsibilities during a critical commercialization and covenant period, increasing execution and governance risk and potentially straining financial oversight.
Scienture Holdings News
4E4 FAQ
What was Scienture Holdings, Inc.’s price range in the past 12 months?
Scienture Holdings, Inc. lowest stock price was €0.07 and its highest was €1.90 in the past 12 months.
What is Scienture Holdings, Inc.’s market cap?
Scienture Holdings, Inc.’s market cap is €12.69M.
When is Scienture Holdings, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Scienture Holdings, Inc.’s earnings last quarter?
Currently, no data Available
Is Scienture Holdings, Inc. overvalued?
According to Wall Street analysts Scienture Holdings, Inc.’s price is currently Overvalued.
Does Scienture Holdings, Inc. pay dividends?
Scienture Holdings, Inc. does not currently pay dividends.
What is Scienture Holdings, Inc.’s EPS estimate?
Scienture Holdings, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scienture Holdings, Inc. have?
Scienture Holdings, Inc. has 40,630,814 shares outstanding.
What happened to Scienture Holdings, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Scienture Holdings, Inc.?
Currently, no hedge funds are holding shares in DE:4E4
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Scienture Holdings, Inc.
TRxADE HEALTH, Inc. operates as health services IT company. It offers an online web-based buying and selling platform for licensed pharmaceutical wholesalers to sell brand, generic, and non-drug products and services to government organizations, hospitals, clinics and independent pharmacies. TRxADE HEALTH, Inc. is headquartered in Tampa, Florida.
Technical Analysis
Options Prices
Currently, No data available
---